Annual Report 2014

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the
Annual Report for 2014 now is available at the company’s website:
www.medivir.com.

-  2014 was an important year for Medivir. We created value in the company
through our sales successes with OLYSIO® (simeprevir), and hence revenues, both
from sales and from royalties. The most important events in 2014 were, without
doubt, the global market launch of OLYSIO® and the approval of OLYSIO® as a
pharmaceutical for the treatment of chronic HCV in Europe, enabling us to launch
it in the Nordic region. We are proud of the fact that our work is helping to
cure seriously ill people and save lives and of the fact that Medivir has
established itself as one of the Nordic region’s leading research based
pharmaceutical companies”, said Medivir’s CEO, Niklas Prager, in his CEO’s
Statement in this year’s Annual Report.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.